ResearcherShowa Pharmaceutical UniversityActive in the last 2 years
Yutaka Masuda
Matched on ORCID iD 0000-0003-3374-2484; OpenAlex author ID A5102791815. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 1
2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 4
- Chk1 inhibition emerges as the most effective partner for PARP inhibition in BRCA-proficient pancreatic cancer. Last author DOI 10.1007/s12672-026-05581-1↗
- Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells. Last author DOI 10.1007/s00280-024-04716-x↗
- Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition … Last author DOI 10.1007/s11010-020-03796-6↗
- Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1. Last author DOI 10.3892/or.2019.7421↗
Closest collaborators
The 1 strongest of 1 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yoshihito Morimoto · 4 shared papers, 2020–2026 · strength 0.82
- Paper Chk1 inhibition emerges as the most effective partner for PARP inhibition in BRCA-proficient pancreatic cancer. DOI 10.1007/s12672-026-05581-1↗
- Paper Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells. DOI 10.1007/s00280-024-04716-x↗
- Paper Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in… DOI 10.1007/s11010-020-03796-6↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.